Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Collegium Pharmaceutical (COLL) Other Working Capital Changes (2016 - 2025)

Collegium Pharmaceutical (COLL) has 10 years of Other Working Capital Changes data on record, last reported at -$5000.0 in Q4 2025.

  • For Q4 2025, Other Working Capital Changes fell 100.26% year-over-year to -$5000.0; the TTM value through Dec 2025 reached -$222000.0, down 101.58%, while the annual FY2025 figure was -$222000.0, 101.58% down from the prior year.
  • Other Working Capital Changes reached -$5000.0 in Q4 2025 per COLL's latest filing, up from -$21.3 million in the prior quarter.
  • Across five years, Other Working Capital Changes topped out at $11.5 million in Q2 2024 and bottomed at -$21.3 million in Q3 2025.
  • Average Other Working Capital Changes over 5 years is $977000.0, with a median of $335000.0 recorded in 2022.
  • The widest YoY moves for Other Working Capital Changes: up 5703.39% in 2025, down 5016.36% in 2025.
  • A 5-year view of Other Working Capital Changes shows it stood at $2.3 million in 2021, then soared by 141.97% to $5.6 million in 2022, then plummeted by 99.25% to $42000.0 in 2023, then skyrocketed by 4538.1% to $1.9 million in 2024, then tumbled by 100.26% to -$5000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Other Working Capital Changes were -$5000.0 in Q4 2025, -$21.3 million in Q3 2025, and $10.8 million in Q2 2025.